Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study. Antivir Ther. 12(8):1157-64. 2007.
Chloe Orkin, Jean-Michel Molina, Pedro Cahn, et al. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. Lancet HIV. 2023 Dec 20:S2352-3018(23)
Taramasso L, Tatarelli P, Ricci E, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018;18(1):357 10.1186/s12879-018-3268-5
Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 372:646-55, 2008.
Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. AIDS. 23:1679-88, 2009.
Echeverria P, Bonjoch A, Puig J, Ornella A, Clotet B, Negredo E : Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med 18 : 782-786, 2017.
Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis.17(1):551. 2017.
Jeong J, Shin JW, Jung SW, et al. Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis. Clin Mol Hepatol. 2021 Dec 28.
Lagathu, C.; Béréziat, V.; Gorwood, J.et al. Metabolic Complications Affecting Adipose Tissue, Lipid and Glucose Metabolism Associated with HIV Antiretroviral Treatment. Expert. Opin. Drug Saf. 2019, 18, 829–840.
Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 18:905-13, 2013.
Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018 Jul 18;67(3):411-419.
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 352:48-62, 2005.
O’Halloran J, Sahrmann J, Olsen M, et al. Incident diabetes associated with integrase strand transfer inhibitor initiation. Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 516.
Jovana Milic, Stefano Renzetti, Davide Ferrari, et al. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens. AIDS.;36(12):1643-1653, 2022
Osiyemi O, De Wit S, Ajana F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Clin Infect Dis.;75(6):975-986, 2022.
Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 349:1993-2003, 2003.
d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 18:1811-17, 2004.
DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, et al. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 356:1723-35, 2007.
Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 201(3):318-30. 2010
Ryom L,Lundgren JD, El-Sadr WM,et al.Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 5(6):e291-e300. 2018
D:A:D Study Group, Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: amulticohort collaboration. Lancet. 371:1417-26, 2008.
Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 22:F17-F24, 2008.
Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr, 51:20-28, 2009.
Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 61:441-47, 2012.
D:A:D Study Group, Friis-Møller N, Ryom R, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Cardiol 23: 214-23, 2016.
Bernard Surial, Frédérique Chammartin, José Damas, et al. Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy, Clin Infect Dis. 2023 Sep 11;77(5):729-737.
Gutierrez J, Albuquerque ALA, Falzon L. HIV infection as vascular risk: A systematic review of the literature and meta-analysis. PLoS One.12(5):e0176686. 2017.
Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis.17(1):551. 2017.
Steven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. The New England journal of medicine. 2023 Aug 24;389(8);687-699.
Melanie A Thompson, Michael A Horberg, Allison L Agwu, ey al. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America, Clin Infect Dis. 2021 Dec 6;73(11):e3572-e3605.
Vincent Lo Re III, Bret Zeldow, Michael J, et al. Risk of Liver Decompensation with Cumulative Use of Mitochondrial Toxic Nucleoside Analogues in HIV/Hepatitis C Virus Coinfection Pharmacoepidemiol Drug Saf. 2017 October ; 26(10): 1172–1181.
Berend J. van Welzen, Tania Mudrikova, Ayman El Idrissi, et al. Review of Non-Alcoholic Fatty Liver Disease in HIV Infected Patients: The Next Big Thing?. Infect Dis Ther (2019) 8:33–50
Michał Biały, Marcin Czarnecki, Małgorzata Inglot, Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy. Viruses2023 Dec 15;15(12):2432
Carlotta Riebensahm, Annalisa Berzigotti, Bernard Surial, et al. Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy.Open Forum Infect Dis. 2022 Nov; 9(11): ofac538
Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 49:626-35, 2009.
Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 21:1273-81, 2007.
Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 6:e22661, 2011.
Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 23:1971-75, 2009.
Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse- transcriptase inhibitor-based therapy. J Infect Dis. 197:102-8, 2008.
Nishijima T, Shimbo T, Komatsu H, et al. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother, 19:850-7, 2013.
Gatanaga H, Nishijima T, Tsukada K, et al. Clinical importance of hyperbeta-2-microglobulinuria in patients with HIV-1 infection on tenofovir-containing antiretroviral therapy. J Acquir Immune Defic Syndr. 65:e155-7, 2014.
Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr.63(4):449-55.2013.
Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis.16(1):43-52. 2016.
Raffi F, Orkin C, Clarke A, et al. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr.75(2):226-31. 2017.
Post FA, Tebas P, Clarke A, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr.74(2):180-4. 2017.
Wohl D, Oka S, Clumeck N, et al. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr.72(1):58-64. 2016.
Arribas JR, Thompson M, Sax PE, et al. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr.75(2):211-218. 2017.
Kensuke Abe, Taku Obara, Satomi Kamio, et al. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study. AIDS Res Ther 2021 Dec 7;18(1):94.
Naoki Kanda, Koh Okamoto, Hisatoshi Okumura, et al. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan HIV Med 2021 Jul;22(6):457-466.
Nishijima T, Mutoh Y, Kawasaki Y, et al. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. AIDS. 2018;32:179-188
Alan Winston, Frank A Post, Edwin DeJesus, et al. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. Lancet HIV. 2018 Apr;5(4):e162-e171
Yanagisawa N, Ando M, Ajisawa A, et al. Clinical Characteristics of Kidney Disease in Japanese HIV-Infected Patients. Nephron Clin Pract. 118:c285-c291, 2011.
Fernando SK, Finkelstein FO, Moore BA, et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 335:89-94, 2008.
Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 21:1119-27, 2007.
Nishijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS, 28:1903-10, 2014.
German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 61(1):32-40, 2012.
Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol, 75:990-6, 2013.
Etienne Mondesert, Jacques Reynes, Alain Makinson, et al. Cystatin C in addition to creatinine for better assessment of glomerular renal function decline in people with HIV receiving antiretroviral therapy. AIDS. 2023 Mar 1;37(3):447-454
Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. J Infect Dis. 210(3):354-62. 2014.
Honda H, Tsukada K, Yazaki H, et al. Low incidence of abacavir-associated hypersensitivity reactions in Japanese HIV-1-infected patients. 4th IAS Conference 2007, Sydney, MOPEB005
Rugang Zhao, Rui Ma, Changsong Zhao, et al. Risk Factors for Osteonecrosis of the Femoral Head in Human Immunodeficiency Virus-Positive Patients: A Retrospective Case-Control Study. AIDS Res Hum Retroviruses.; 38(11):869-874, 2022.
Cornelia Bayard, Bruno Ledergerber, Markus Flepp, et al. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. Open Forum Infect Dis.; 4(4): ofx177, 2017.
Biver E. Osteoporosis and HIV Infection.Calcif Tissue Int. 2022 May;110(5):624-640
Brown TT, Qaquish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20:2165-74, 2006.
Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 22:395-402, 2008.
Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 23:1297-1310, 2009.
Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 23:1519-29, 2009.
María Victoria Delpino, Jorge Quarleri, Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis. Front. Endocrinol., Sec. Bone Research, Volume 11, 2020.
Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 13:1077-82, 2008.
Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 25:387-94, 2009.
Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med, 161:1-10, 2014.
Alessandro Cozzi-Lepri, Lars Peters, Annegret Pelchen-Matthews, et al. Observational cohort study of rilpivirine (RPV) utilization in Europe, AIDS Res Ther. 2022 Aug 6;19(1):38.
Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin Infect Dis. 2021 Jul 1;73(1):33-42.
de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 30(18):2831-4. 2016.
Arturo Ciccullo, Gianmaria Baldin, Vanni Borghi, et al. Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort. Viruses.;14(1):163, 2022.
Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 18(1):56-63. 2017.
Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis.17(1):622. 2017.
Wohl D, Clarke A, Maggiolo F, et al. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018 Oct;11(5):561-573.
M Li, Y Foli, Z Liu, et al. High frequency of mitochondrial DNA mutations in HIV-infected treatment-experienced individuals. HIV Med. 2017 Jan;18(1):45-55.
Marcello Pinti, Paolo Salomoni, Andrea Cossarizza, et al. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta. 2006 May-Jun;1757(5-6):700-7.
Korencak, M, Byrne, M., Richter, E, et al. Effect of HIV infection and antiretroviral therapy on immune cellular functions. JCI Insight 2019, 4.
Ganta, K.K, Mandal, A, Chaubey, B. Depolarization of mitochondrial membrane potential is the initial event in non-nucleoside reverse transcriptase inhibitor efavirenz induced cytotoxicity. Cell Biol. Toxicol. 2017, 33, 69–82.
McComsey G. and Lonergan JT. Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management. J Acquir Immune Defic Syndr. 37:S30-S35, 2004.
A Arenas-Pinto, AD Grant, S Edwards, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 79:340-3, 2003.
Schambelan M, Benson CA, Carr A, et al; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 31:257-75, 2002.
Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet. 351:1881-3, 1998.
McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 53(2):185-96. 2011.
Reneé de Waal, Karen Cohen, Gary Maartens, Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013 May 28;8(5):e63623.
Ricardo H Roda, Ahmet Hoke. Mitochondrial dysfunction in HIV-induced peripheral neuropathy. Int Rev Neurobiol. 2019:145:67-82.
HIV 感染症治療薬共同使用成績調査 2022報告書, シミック株式会社
Sax PE, Erlandson KM, Lake JE et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020; 71(6):1379-1389.
Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019; 381(9):803-815.
Bourgi K, Rebeiro PF, Turner M et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020; 70(7):1267-1274.
Bourgi K, Jenkins C, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 Apr;23(4):e25484.
Bedimo R, Li X, Adam-Huet B, et al. Different BMI changes following PI-and InSTI-based ART initiation by sex and race. Presented at: Conference on Retroviruses and Opportunistic Infections; 2019; Seattle, WA.
Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 Oct;7(10):e666-e676.
McComsey GA, Sax P, Althoff KN, et al. Weight gain after switching different integrase strand transfer inhibitors(InSTIs). Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 503.
Orkin, C.; Oka, S.; Philibert, P.; Brinson, C.; Bassa, A.; Gusev, D.; Degen, O.; García, J.G.; Morell, E.B.; Tan, D.H.S.; et al. Long-Acting Cabotegravir plus Rilpivirine for Treatment in Adults with HIV-1 Infection: 96-Week Results of the Randomised, Open-Label, Phase 3 FLAIR Study. Lancet HIV.: 8, e185-e196, 2021.
Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021 Jan 1;35(1):91-99.
Fields SD, Tung E. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.Infect Dis Ther. 2021 Mar;10(1):165-186
Erlandson, K.M.; Carter, C.C.; Melbourne, K.; Brown, T.T.; Cohen, C.; Das, M.; Esser, S.; Huang, H.; Koethe, J.R.; Martin, H.; et al. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin. Infect. Dis.:73, 1440–1451.
Emma M Kileel, Carlos D Malvestutto, et al. Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE). Clinical Infectious Diseases, Volume 76, Issue 11, 1 June 2023, Pages 2010-2013
Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019; 47(1): 95-102.
Patrick WG Mallon, Laurence Brunet, Ricky K Hsu, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021 Apr; 24(4): e25702
Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana, et al. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC+DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clinical Infectious Diseases, Volume 76, Issue 8, 15 April 2023, Pages 1492-1495
Kauppinen, Kai Juhani, Aho, Inka, et al. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain. AIDS 36(10):p 1337-1344, August 1, 2022.
Sudipa Sarkar, Todd T. Brown, et al. CROI 2023: Metabolic and Other Complications of HIV Infection. Top Antivir Med. 2023 Jun; 31(4): 538-542
Bedimo R, Adams-Huet B, Taylor BS, et al. Integrase inhibitor-based HAART is associated with greater BMI gains in blacks, Hispanics and women. Presented at: IDWeek; 2018; San Fransisco, CA.
Wu KS, Anderson C, Little SJ. Integrase Strand Transfer Inhibitors Play the Main Role in Greater Weight Gain Among Men With Acute and Early HIV Infection. Open Forum Infect Dis. 2020 Dec 28;8(1)
Kumar S, Samaras K. et al. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018 Nov 27;9:705.
Kenza Ngono Ayissi, Jennifer Gorwood, Laura Le Pelletier, et al. Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes. Cells. 2022 Jun; 11(11): 1841,
IkRak Jung, Becky Tu-Sekine, Sunghee Jin,et al. Dolutegravir Suppresses Thermogenesis via Disrupting Uncoupling Protein 1 Expression and Mitochondrial Function in Brown/Beige Adipocytes in Preclinical Models. J Infect Dis. 2022 Nov 1; 226(9): 1626–1636.
Hill A, Mac Cann KM, Polkington V, et al. Risk of metabolic syndrome, diabetes, and cardiovascular disease in Advance trial. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020; Boston, abstract 81.
Petoumenos K, Kuwanda L, Ryom L, et al. Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. J Acquir Immune Defic Syndr. 2021 Apr 15;86(5):579-586.
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, et al. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study. Clin Infect Dis. 2023 May 1; 76(9): 1646–1654.
Kikuchi Y, Genka I, Ishizaki A. et al. Serious Bradyarrhythmia That Was Possibly Induced by Lopinavir-Ritonavir in 2 Patients with Acquired Immunodeficiency Syndrome. Clin Infect Dis. 35(4), 488-90, 2002.
Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 22(11):1382-4, 2008.
Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 45(3):289-94, 2015.
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med.379(10):979-81. 2018.
Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827-840.
Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception-additional surveillance data from Botswana. N Engl J Med. 2019;381(9):885-887.
Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference 2020. #OAXLB0102.